Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This research application will explore the impact of the Non-nucleoside reverse transcriptase
inhibitor (NNRTI) doravirine in the setting of established Nucleoside reverse transcriptase
inhibitors (NRTIs) backbone [Tenofovir alafenamide (TAF) / Emtricitabine (FTC) as a possible
therapeutic strategy to minimize the detrimental impact of ART-related toxicities on
metabolism and instigators of atherosclerosis. Given the possible favorable role of NNRTI in
pathogenesis of HIV-related dyslipidemia and cardiovascular disease (CVD), this research will
provide mechanistic insights into HIV pathogenesis and safety data regarding doravirine
(DOR). These data may promote DOR as a robust "HDL friendly" and "metabolism friendly",
therapeutic agent that may attenuate morbidity in chronic treated HIV infection. Towards this
aim, the investigators will study DOR-related effects on HDL (HDL-C levels and function) and
ex vivo assays that determine key molecular determinants of atherogenesis.